• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Alcohol Addiction - Pipeline Review, H2 2012 Product Image

Alcohol Addiction - Pipeline Review, H2 2012

  • ID: 2298812
  • October 2012
  • 135 pages
  • Global Markets Direct

Alcohol Addiction – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Alcohol Addiction - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Alcohol Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alcohol Addiction. Alcohol Addiction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Alcohol Addiction.
- A review of the Alcohol Addiction products under development by companies and universities/research institutes READ MORE >

2
List of Tables 9
List of Figures 10
Introduction 11
REPORT COVERAGE 11
Alcohol Addiction Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Alcohol Addiction 13
Alcohol Addiction Therapeutics under Development by Companies 15
Alcohol Addiction Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 20
Comparative Analysis 20
Mid Clinical Stage Products 21
Comparative Analysis 21
Early Clinical Stage Products 22
Comparative Analysis 22
Discovery and Pre-Clinical Stage Products 23
Comparative Analysis 23
Alcohol Addiction Therapeutics – Products under Development by Companies 24
Alcohol Addiction Therapeutics – Products under Investigation by Universities/Institutes 25
Companies Involved in Alcohol Addiction Therapeutics Development 27
Tekmira Pharmaceuticals Corp. 27
Alkermes, Inc. 28
Mitsubishi Tanabe Pharma Corporation 29
Nippon Shinyaku Co., Ltd. 30
AEterna Zentaris Inc. 31
Catalyst Pharmaceutical Partners, Inc. 32
Biotie Therapies Corp. 33
Omeros Corporation 34
Vanda Pharmaceuticals Inc. 35
Sihuan Pharmaceutical Holdings Group Ltd. 36
Heptares Therapeutics Ltd. 37
Alcohol Addiction – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
nalmefene - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
samidorphan - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AEZS-123 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
vigabatrin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
acamprosate calcium - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
modafinil - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
guanfacine hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
varenicline tartrate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
divalproex sodium ER - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ondansetron - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
aprepitant - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
aprepitant - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
gabapentin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
baclofen - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
bupropion hydrochloride - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
naltrexone ER - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Naltrexone + Aripiprazole - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Acamprosate + Yohimbine + Mcpp - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Nicoderm CQ + Nicotine Nasal Spray - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
acamprosate calcium - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
gabapentin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
levetiracetam XR - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
oxytocin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
atomoxetine hydrochloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
varenicline tartrate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Fluoxetine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
VLY-686 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
GSK-561679 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
olanzapine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
duloxetine hydrochloride - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Quetiapine + Mirtazapine - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
pregabalin - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Ondansetron + Topiramate - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Topiramate + Naltrexone - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Ondansetron + Topiramate + Naltrexone - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
sulfasalazine - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
vigabatrin - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
aripiprazole - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Risperidone + Desipramine - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
doxazosin mesylate - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
MT-7716 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
metadoxine - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Drug For Alcohol Addiction And Anxiety Disorders - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
nalmefene - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
TKM-ALDH2 - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
Drug targeting Orexin 1 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Alcohol Addiction Therapeutics – Drug Profile Updates 116
Alcohol Addiction Therapeutics – Discontinued Products 122
Alcohol Addiction Therapeutics - Dormant Products 123
Alcohol Addiction – Product Development Milestones 125
Featured News & Press Releases 125
Mar 27, 2012: Nippon Shinyaku Submits New Drug Application For Acamprosate Calcium 125
Mar 05, 2012: Biotie Announces Presentation Of Positive Phase III Results Of Selincro At 20th European Congress Of Psychiatry 125
Dec 21, 2011: Lundbeck Submits European Marketing Authorization Application For Selincro For Treatment Of Alcohol Dependence 126
Jun 15, 2011: Biotie Completes Phase III Program With Nalmefene In Alcohol Dependence 127
Mar 29, 2011: Catalyst Announces Commencement Of CPP-109 Investigator-Sponsored Study In Cocaine And Alcohol Co-Dependent Patients 129
Jan 03, 2011: Lundbeck Reports Positive Results From First Two Nalmefene Phase III Studies In Alcohol Dependence 129
Dec 08, 2010: Alkermes Announces Positive Phase II Study Results Of ALKS 33 In Alcohol Dependence 130
Jul 07, 2009: New Data Published By AEterna Zentaris On Its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports Its Use In Alcohol Addiction 131
Dec 15, 2008: Lundbeck Initiates Phase III Clinical Trials With Nalmefene As A New Method Of Treatment Of Alcohol Dependence 132
Jan 02, 2008: Nalmefene United Kingdom And Ireland Rights Acquired By Lundbeck 133
Appendix 134
Methodology 134
Coverage 134
Secondary Research 134
Primary Research 134
Expert Panel Validation 134
Contact Us 135
Disclaimer 135

List of Tables
Number of Products Under Development for Alcohol Addiction, H2 2012 13
Products under Development for Alcohol Addiction – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Investigation by Universities/Institutes, H2 2012 18
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 19
Comparative Analysis by Late Stage Development, H2 2012 20
Comparative Analysis by Mid Clinical Stage Development, H2 2012 21
Comparative Analysis by Early Clinical Stage Development, H2 2012 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 23
Products under Development by Companies, H2 2012 24
Products under Investigation by Universities/Institutes, H2 2012 25
Tekmira Pharmaceuticals Corp., H2 2012 27
Alkermes, Inc., H2 2012 28
Mitsubishi Tanabe Pharma Corporation, H2 2012 29
Nippon Shinyaku Co., Ltd., H2 2012 30
AEterna Zentaris Inc., H2 2012 31
Catalyst Pharmaceutical Partners, Inc., H2 2012 32
Biotie Therapies Corp., H2 2012 33
Omeros Corporation, H2 2012 34
Vanda Pharmaceuticals Inc., H2 2012 35
Sihuan Pharmaceutical Holdings Group Ltd., H2 2012 36
Heptares Therapeutics Ltd., H2 2012 37
Assessment by Monotherapy Products, H2 2012 38
Assessment by Combination Products, H2 2012 39
Assessment by Stage and Route of Administration, H2 2012 41
Assessment by Stage and Molecule Type, H2 2012 43
Alcohol Addiction Therapeutics – Drug Profile Updates 116
Alcohol Addiction Therapeutics – Discontinued Products 122
Alcohol Addiction Therapeutics – Dormant Products 123

List of Figures
Number of Products under Development for Alcohol Addiction, H2 2012 13
Products under Development for Alcohol Addiction – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 17
Late Stage Products, H2 2012 20
Mid Clinical Stage Products, H2 2012 21
Early Clinical Stage Products, H2 2012 22
Discovery and Pre-Clinical Stage Products, H2 2012 23
Assessment by Monotherapy Products, H2 2012 38
Assessment by Combination Products, H2 2012 39
Assessment by Route of Administration, H2 2012 40
Assessment by Stage and Route of Administration, H2 2012 41
Assessment by Molecule Type, H2 2012 42
Assessment by Stage and Molecule Type, H2 2012 43

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos